Similarly, doses of sulfonylureas or insulin often need reduction to prevent hypoglycemia
Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-Mono): A Double-Blind, Multicentre, Randomised, Phase 3 Trial
However, 82% of those on tirzepatide reached this significant clinical milestone, compared to only 67% of those on semaglutide
Tirzepatide and semaglutide are appropriate for patients who: Have at least 20 pounds of fat to lose Struggle with cravings, overeating, or stalled progress despite trying on their own Have signs of insulin resistance, metabolic syndrome, or hormone-related weight gain Want a physician-led, sustainable plan that protects metabolism, muscle, and appearance Who Should Not Use Tirzepatide (Zepbound) or Semaglutide (Wegovy)